Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 335

Blog

Development of ImmunOncoTool
Conditions:   Cancer;   Cancer, Treatment-Related
Intervention:   Behavioral: ImmunOncoTool Condition
Sponsors:   Northwestern University;   American Cancer Society, Inc.;   Bristol-Myers Squibb;   Melanoma Research Foundation Breakthrough Consortium
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 15, 2020 / by / in
ZW25 in Women With Endometrial Cancers
Conditions:   Endometrial Cancer;   Carcinosarcoma
Intervention:   Drug: ZW25
Sponsors:   Memorial Sloan Kettering Cancer Center;   Zymeworks Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 15, 2020 / by / in
AIMS Medical Outcomes Study
Conditions:   Mental Health Issue;   PTSD;   Pain;   Chronic Pain;   Chronic Disease
Intervention:  
Sponsor:   Advanced Integrative Medical Science Institute
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 15, 2020 / by / in
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Condition:   Non-small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Atezolizumab;   Drug: Tiragolumab;   Drug: Durvalumab
Sponsor:   Hoffmann-La Roche
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 15, 2020 / by / in
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
Conditions:   Gastric Cancer;   Gastric Adenocarcinoma;   GastroEsophageal Cancer
Interventions:   Drug: DKN-01 300mg;   Drug: DKN-01 600mg;   Drug: Tislelizumab 200mg;   Drug: Oxaliplatin 130mg/m2;   Drug: Capecitabine 1000mg/ m2 BID
Sponsors:   Leap Therapeutics, Inc.;   BeiGene
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 14, 2020 / by / in
Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients
Conditions:   Breast Cancer;   Gastric Cancer;   Cancer
Intervention:   Biological: TAEK-VAC-HerBy
Sponsor:   Bavarian Nordic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 14, 2020 / by / in
Mindfulness in Endometrial and Cervical Cancer
Conditions:   Gynecologic Cancer;   Endometrial Cancer;   Cervical Cancer;   Quality of Life;   Opioid Use
Intervention:   Behavioral: Headspace Smartphone Application
Sponsor:   St. Louis University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 14, 2020 / by / in
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers
Conditions:   Colorectal Carcinoma;   Gastric Adenocarcinoma;   Esophageal and GEJ Adenocarcinoma;   Cholangiocarcinoma;   Gallbladder Carcinoma
Interventions:   Drug: tucatinib;   Drug: trastuzumab;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: fluorouracil
Sponsor:   Seattle Genetics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 13, 2020 / by / in
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Condition:   B-Cell Malignancies
Interventions:   Drug: Parsaclisib;   Drug: parsaclisib + itacitinib
Sponsor:   Incyte Corporation
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 13, 2020 / by / in
Study of Pembrolizumab Plus Trastuzumab or Trastuzumab Alone After Surgery in Patients With Esophagogastric Tumors
Conditions:   Esophagogastric Tumors;   Gastric Cancer;   Gastric Tumor;   Esophageal Cancer;   Esophageal Neoplasms;   Esophageal Tumor;   GastroEsophageal Cancer;   Gastroesophageal Junction Adenocarcinoma;   Gastroesophageal Junction Tumor;   Gastroesophageal Junction Cancer
Interventions:   Drug: Trastuzumab;   Drug: Pembrolizumab
Sponsor:   Memorial Sloan Kettering Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 13, 2020 / by / in